Last reviewed · How we verify
ranibizumab and dexamethasone
At a glance
| Generic name | ranibizumab and dexamethasone |
|---|---|
| Sponsor | Subhransu K. Ray, M.D., Ph.D. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Intraocular pressure increased
- Intraocular Pressure Increased
- Conjunctival haemorrhage
- Cataract
- Conjunctival Haemorrhage
- Visual acuity reduced
- Vitreous Haemorrhage
- Macular oedema
- Vitreous floaters
- Eye pain
- Visual Acuity Reduced
- Cataract Subcapsular
Key clinical trials
- Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification (PHASE4)
- Systemic and Local Inflammatory Biomarkers in the Treatment of Refractory Diabetic Macular Edema
- Study on Precision Treatment of Diabetic Retinopathy Macular Edema Guided by Real-time OCT During Operation (PHASE3)
- Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (PHASE3)
- Intravitreal Ranibizumab Versus Its Combination With Dexamethasone in The Treatment of Diabetic Macular Edema (PHASE3)
- Diabetic Macular Edema (DME) Treatment With Ranibizumab and Dexamethasone or Ranibizumab Only. (NA)
- Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema (PHASE4)
- Anti-VEGF Therapy Versus Dexamethasone Implant for DME (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ranibizumab and dexamethasone CI brief — competitive landscape report
- ranibizumab and dexamethasone updates RSS · CI watch RSS
- Subhransu K. Ray, M.D., Ph.D. portfolio CI